Aida Pharmaceuticals Initiates Preclinical Research of Potential Anti-Cancer Treatment Vasostatin-Apo2L

Company expands treatment pipeline with new recombinant genetic treatment

HANGZHOU, China | Mar 15, 2007 | 
Aida Pharmaceuticals, Inc. (OTC Bulletin Board: AIDA - News), one of mainland China's leading pharmaceutical companies, today announced the Company's subsidiary, Shanghai Qiaer Biotechnology, has initiated preclinical research of the potential anti- cancer treatment Vasostatin-Apo2L.

Vasostatin-Apo2L is a recombinant fusion protein with the potential to inhibit tumor growth. The treatment may integrate the function of an extracted fragment of Vasostatin, an inhibitor of angiogenesis and tumor growth with similar results of Rh-Apo2L, the Company's existing anti-cancer treatment currently in Phase II trials, which induces the apoptosis (cellular death) of cancer cells. Scientists from Shanghai Qiaer Biotechnology are researching the potential incorporation of both treatments, Vasostatin-Apo2L and Rh-Apo2L, to increase the overall efficacy of cancer treatment.

Chief Executive Officer of Shanghai Qiaer Biotechnology, Jinsong Zhou, stated, "Earlier this year we announced the formal commencement of Phase II trials of Rh-Apo2L; the trials are underway and moving forward and we anticipate announcing preliminary results later this year. Our researchers have discovered that Vasostatin-Apo2L - a derivative of Rh-Apo2L - may work in tandem with Rh-Apo2L to more effectively treat some forms of cancer. Our scientists intend to leverage their experience and knowledge gained from the research and development of Rh-Apo2L and we believe that Vasostatin-Apo2L, either as a stand alone genetically engineered therapy or as a commingled medicinal approach, will materially increase the efficacy of cancer treatment."

Chairman and Chief Executive Officer of Aida Pharmaceuticals, Biao Jin, added, "Aida Pharmaceuticals' scientists already have an extensive knowledge of recombinant fusion proteins from the research and development of Rh-Apo2L. As a result of this intellectual property, the Company has been successful in receiving support and sponsorship from the scientific community and investors, including several national and municipal funds. Our entrenched position in the Chinese bio-pharmaceutical market along with what we already know about Vasostatin-Apo2L, leads me to believe that Aida Pharmaceuticals and Shanghai Qiaer Biotechnology will be able to cost effectively expedite preclinical research. This new treatment extends Aida Pharmaceuticals' pipeline to eight potential treatments and represents the Company's industry advantage in anti- cancer discovery and potential treatment."

About Aida Pharmaceuticals:

Aida Pharmaceuticals is a product-focused pharmaceuticals company engaged in the formulation, clinical testing, registration, manufacture, sales and marketing of advanced pharmaceutical and genetic products in mainland China. The Company's mission is to discover, develop and market meaningful new therapies that improve human health. Aida Pharmaceuticals, in operation since March 1999, is headquartered in Hangzhou, China with manufacturing, distribution and sales points throughout mainland China. Aida is GMP certified in China and ISO9002 certified for quality assurance and ISO14000 certified for ecologically-friendly practices. Aida is now producing and marketing a patented prescription drug in China: Etimicin Sulfate. It is the first antibiotic developed in China and is regarded as a category "A" drug by the State Food and Drug Administration of China.

Contact Information:
Aida Pharmaceuticals, Inc.
31 Dingjiang Road
Jianggan District
Hangzhou, China 310016

Investor Relations:
Equity Performance Group
Bethany Tomich
(617) 723-1465
This email address is being protected from spambots. You need JavaScript enabled to view it.

Safe Harbor Statement:
Under the Private Securities Litigation Reform Act of 1995:

This press release includes certain "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995. These statements are based on Aida Pharmaceuticals, Inc.'s management's current expectations and are subject to risks and uncertainties and changes in circumstances. All forward-looking statements included in this press release are based upon information available to Aida Pharmaceuticals, Inc. as of the date of the press release, and it assumes no obligation to update or alter its forward looking statements whether as a result of new information, future events or otherwise. These forward-looking statements may relate to, among other things, plans and timing for the introduction or enhancement of our services and products, clinical trial results, statements about future market conditions, supply and demand conditions, and other expectations, intentions and plans contained in this press release that are not historical fact. Further information on risks or other factors that could affect Aida Pharmaceuticals, Inc.'s results of operations is detailed in its filings with the United States Securities and Exchange Commission available at

SOURCE: Aida-Pharmaceuticals, Inc.

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2021 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up